SiLaC® with EPSiT®: early outcomes of laser-endoscopic therapy for pilonidal sinus

BackgroundPilonidal sinus disease (PSD) commonly affects young adults and often requires repeated interventions with prolonged healing times. We evaluated a combined approach using Sinus Laser Ablation of the Cyst (SiLaC®) and Endoscopic Pilonidal Sinus Treatment (EPSiT®) to investigate postoperativ...

Full description

Saved in:
Bibliographic Details
Main Author: Mustapha Ouali
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Surgery
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fsurg.2025.1587467/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850179519620579328
author Mustapha Ouali
author_facet Mustapha Ouali
author_sort Mustapha Ouali
collection DOAJ
description BackgroundPilonidal sinus disease (PSD) commonly affects young adults and often requires repeated interventions with prolonged healing times. We evaluated a combined approach using Sinus Laser Ablation of the Cyst (SiLaC®) and Endoscopic Pilonidal Sinus Treatment (EPSiT®) to investigate postoperative pain, healing time, and recurrence.MethodsThis retrospective, single-center study included 83 patients (aged 15–50) treated from January 2021 to December 2023 at Proctolaser Clinic, Tunisia. Under local, regional, or general anesthesia, patients underwent endoscopic debridement (EPSiT®) followed by diode laser ablation (SiLaC®) of sinus tracts. Data on operative time, Visual Analogue Scale (VAS) pain score, healing time to complete epithelialization, recurrence, and time to return to work were collected. All patients had at least 6 months of follow-up; a subset was followed up to 1 year.ResultsThe mean operative time was 25 ± 5.4 min. Mean VAS pain score at 24 h was 1.2 ± 0.6, and 92.3% of patients resumed work or normal activities within 24 h. Mean healing time was 17.3 days, with 95% achieving complete epithelialization by 3 weeks. The overall recurrence rate at 6 months was 3.6% (3/83). Two recurrences (3.3%) occurred in patients with primary PSD, and one recurrence (4.3%) occurred in a patient with recurrent PSD. Minor infections occurred in 1.2% (1/83) of patients and resolved with oral antibiotics. Aesthetic satisfaction was high; 88% rated outcomes “excellent.”ConclusionsCombining SiLaC® with EPSiT® for pilonidal sinus disease appears safe and effective, featuring minimal pain, rapid return to daily activities, low recurrence, and excellent cosmetic results. A longer-term, multicenter approach is recommended to confirm durability and cost-effectiveness.
format Article
id doaj-art-052cd09c8f4c4b05ae1b71e1fb20c4f0
institution OA Journals
issn 2296-875X
language English
publishDate 2025-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Surgery
spelling doaj-art-052cd09c8f4c4b05ae1b71e1fb20c4f02025-08-20T02:18:28ZengFrontiers Media S.A.Frontiers in Surgery2296-875X2025-04-011210.3389/fsurg.2025.15874671587467SiLaC® with EPSiT®: early outcomes of laser-endoscopic therapy for pilonidal sinusMustapha OualiBackgroundPilonidal sinus disease (PSD) commonly affects young adults and often requires repeated interventions with prolonged healing times. We evaluated a combined approach using Sinus Laser Ablation of the Cyst (SiLaC®) and Endoscopic Pilonidal Sinus Treatment (EPSiT®) to investigate postoperative pain, healing time, and recurrence.MethodsThis retrospective, single-center study included 83 patients (aged 15–50) treated from January 2021 to December 2023 at Proctolaser Clinic, Tunisia. Under local, regional, or general anesthesia, patients underwent endoscopic debridement (EPSiT®) followed by diode laser ablation (SiLaC®) of sinus tracts. Data on operative time, Visual Analogue Scale (VAS) pain score, healing time to complete epithelialization, recurrence, and time to return to work were collected. All patients had at least 6 months of follow-up; a subset was followed up to 1 year.ResultsThe mean operative time was 25 ± 5.4 min. Mean VAS pain score at 24 h was 1.2 ± 0.6, and 92.3% of patients resumed work or normal activities within 24 h. Mean healing time was 17.3 days, with 95% achieving complete epithelialization by 3 weeks. The overall recurrence rate at 6 months was 3.6% (3/83). Two recurrences (3.3%) occurred in patients with primary PSD, and one recurrence (4.3%) occurred in a patient with recurrent PSD. Minor infections occurred in 1.2% (1/83) of patients and resolved with oral antibiotics. Aesthetic satisfaction was high; 88% rated outcomes “excellent.”ConclusionsCombining SiLaC® with EPSiT® for pilonidal sinus disease appears safe and effective, featuring minimal pain, rapid return to daily activities, low recurrence, and excellent cosmetic results. A longer-term, multicenter approach is recommended to confirm durability and cost-effectiveness.https://www.frontiersin.org/articles/10.3389/fsurg.2025.1587467/fullpilonidal sinus diseaseSiLaC®EPSiT®laser therapyminimally invasive surgeryrecurrence
spellingShingle Mustapha Ouali
SiLaC® with EPSiT®: early outcomes of laser-endoscopic therapy for pilonidal sinus
Frontiers in Surgery
pilonidal sinus disease
SiLaC®
EPSiT®
laser therapy
minimally invasive surgery
recurrence
title SiLaC® with EPSiT®: early outcomes of laser-endoscopic therapy for pilonidal sinus
title_full SiLaC® with EPSiT®: early outcomes of laser-endoscopic therapy for pilonidal sinus
title_fullStr SiLaC® with EPSiT®: early outcomes of laser-endoscopic therapy for pilonidal sinus
title_full_unstemmed SiLaC® with EPSiT®: early outcomes of laser-endoscopic therapy for pilonidal sinus
title_short SiLaC® with EPSiT®: early outcomes of laser-endoscopic therapy for pilonidal sinus
title_sort silac r with epsit r early outcomes of laser endoscopic therapy for pilonidal sinus
topic pilonidal sinus disease
SiLaC®
EPSiT®
laser therapy
minimally invasive surgery
recurrence
url https://www.frontiersin.org/articles/10.3389/fsurg.2025.1587467/full
work_keys_str_mv AT mustaphaouali silacwithepsitearlyoutcomesoflaserendoscopictherapyforpilonidalsinus